Business Wire

The Pokémon Company International and Fathom Events Bring Pokémon the Movie: I Choose You! to Theaters for a Two-Day Cinema Event

Del

The new animated film Pokémon the Movie: I Choose You!, based on the globally popular Pokémon brand, is coming to movie theaters around the world for two days this November. The Pokémon Company International announced today that it has entered into an agreement with Fathom Events, the recognized leader in event cinema distribution, for international theatrical rights (outside of Asia) to the highly-anticipated movie.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170731005842/en/

Pokémon the Movie: I Choose You! (Photo: Business Wire)

Pokémon the Movie: I Choose You! (Photo: Business Wire)

Pokémon the Movie: I Choose You! is an origin story highlighting Ash and Pikachu’s first meeting and their adventures as they search for the Legendary Pokémon Ho-Oh. The iconic pair encounter familiar faces along the way, new characters including Trainers Verity and Sorrel, and even a mysterious new Mythical Pokémon, Marshadow. Challenges and epic Pokémon battles abound in this unique new story about the beginning of one of the most beloved friendships in popular culture.

“As an origin story, Pokémon the Movie: I Choose You! is the perfect way for a new generation of Pokémon fans to experience the beginning of Ash and Pikachu’s friendship, and it offers longtime fans an exciting new look into the start of their epic adventures,” said Colin Palmer, Vice President of Marketing at The Pokémon Company International. “We’re excited to work with Fathom Events, whose expertise in unique theatrical event activations will offer families and fans the opportunity to come together and experience the excitement of Pokémon animation on the big screen.”

Pokémon the Movie: I Choose You! will be shown in movie theaters for two days only, on Sunday, November 5, and Monday, November 6, 2017, in select international markets. More details, including screening times and special offers, will be available soon. The movie is already winning over crowds of moviegoers in Japan, where the franchise began, as it opened at the top of the charts for its first weekend.

“Fathom Events is thrilled to work with The Pokémon Company International to bring Pokémon the Movie: I Choose You! to the U.S. and international event cinema markets,” Fathom Events CEO-elect Ray Nutt said. “We can’t wait to deliver a high-caliber Pokémon cinema event that fans around the world won’t want to miss.”

More information, including participating theater locations, ticketing dates, and event details, will be available soon on www.FathomEvents.com. Parents and fans can visit the site now to sign up and receive updates and details about the upcoming limited theatrical release.

To learn more about Pokémon animation, visit www.Pokemon.com and join the conversation on social media with #PokemonIChooseYou.

About Pokémon

The Pokémon Company International, a subsidiary of The Pokémon Company in Japan, manages the property outside of Asia and is responsible for brand management, licensing and marketing, the Pokémon Trading Card Game, the animated TV series, home entertainment, and the official Pokémon website. Pokémon was launched in Japan in 1996 and today is one of the most popular children’s entertainment properties in the world. For more information, visit www.pokemon.com.

About Fathom Events

Fathom Events is recognized as the leading domestic distributor of event cinema with participating affiliate theaters in all 100 of the top Designated Market Areas®, and ranks as one of the largest overall distributors of content to movie theaters. Owned by AMC Entertainment Inc. (NYSE: AMC), Cinemark Holdings, Inc. (NYSE: CNK) and Regal Entertainment Group (NYSE: RGC) (known collectively as AC JV, LLC), Fathom Events offers a variety of one-of-a-kind entertainment events such as live, high-definition performances of the Metropolitan Opera, dance and theatre productions like the Bolshoi Ballet and National Theatre Live, sporting events like “Canelo Álvarez vs. Julio César Chávez, Jr.,” concerts with artists like Michael Bublé, Rush and Mötley Crüe, the yearlong TCM Big Screen Classics film series, inspirational events such as To Joey With Love and Facing Darkness, and anime titles such as Princess Mononoke and Spirited Away. Fathom Events takes audiences behind the scenes and offers unique extras including audience Q&As, backstage footage and interviews with cast and crew, creating the ultimate VIP experience. Fathom Events’ live digital broadcast network (“DBN”) is the largest cinema broadcast network in North America, bringing live and pre-recorded events to 897 locations and 1,387 screens in 181 DMAs. For more information, visit www.fathomevents.com.

Contact information

Fathom Events
Jessica Nelson, 720-262-2753
jnelson@fathomevents.com
or
Katherine Schwappach, 720-262-2713
kschwappach@fathomevents.com
or
The Pokémon Company International
Daniel Benkwitt, 425-229-6070
d.benkwitt@pokemon.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AURAK Gains SACSCOC Accreditation15.12.2018 10:49Pressemelding

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha